Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
European Medical Solutions S.A. is a Belgium-based company specializing in the design, development, and manufacturing of advanced medical imaging systems. Its product portfolio focuses primarily on digital radiology and bone densitometry technologies, serving diagnostic needs across various healthcare settings. The company offers innovative solutions including R/F systems like PLATINUM NEO and OPTIMA dRF, ambulatory and operating room radiography equipment, mammography, and retrofit kits, addressing comprehensive imaging workflows. Founded in 1979 and formerly known as DMS Imaging, it rebranded to European Medical Solutions in June 2024 and operates internationally through an extensive network of over 140 distributors and subsidiaries. With a strategic emphasis on technological innovation, it aims to deliver high-quality imaging tools that support precise diagnostics and patient care. European Medical Solutions plays a significant role in the specialized medical devices sector by supplying critical digital imaging solutions essential for modern medical diagnostics and treatment planning.
€4.92
+€0.00 (+0.00%)
Price from 2 days ago
Operating margin is thin at 5.37%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 10.6% YoY with margins expanding 2.2pp.
Net debt of €13M represents 5.3x FCF, leverage limits flexibility.
11.3x earnings, 8.3x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€50M
▲ +10.6% YoY
Net Income (TTM)
€2M
▲ +237.0% YoY
Op. Margin
5.37%
▲ +2.2pp YoY
ROIC
8.30%
▲ +4.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€2M
▲ +345.5% YoY
Op. Cash Flow (TTM)
€5M
▲ +1212.8% YoY
Net Debt
€13M
Cash & Equiv.
€6M
3Y CAGR: +12.3%
Continue Research
At a P/E of 11.3 and a price-to-free-cash-flow of 8.3, European Medical Solutions (ALEMS.XBRU) trades below a two-stage DCF intrinsic value of about €7.08 per share, so at €4.92 the stock looks undervalued (43.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, European Medical Solutions scores 75/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €7.08 per share for ALEMS.XBRU, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €5.31. At today's €4.92, that puts the stock about 43.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
European Medical Solutions scores 75 out of 100 on Intrinsiqq's quality score, passing 6 of 7 checks, which makes it a solid business on these measures. Recent fundamentals include a 5.4% operating margin and a 8.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. ALEMS.XBRU currently trades below its estimated intrinsic value and scores 75/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.